Literature DB >> 29282756

Influenza B virus infection and Stevens-Johnson syndrome.

Rebecca L Tamez1, Whitney V Tan2, John T O'Malley3, Karen R Broder4, Maria C Garzon2,5, Philip LaRussa5, Christine T Lauren2,5.   

Abstract

A 2-year-old boy with influenza B infection and rapidly worsening targetoid skin lesions with mucosal involvement was diagnosed with Stevens-Johnson syndrome (SJS) and treated with oseltamivir and intravenous immunoglobulin, with resolution of illness. Subsequent quadrivalent inactivated influenza vaccine was well tolerated. This case highlights the rarity of SJS in the setting of influenza B infection and addresses the safety of administering subsequent influenza vaccines to such individuals.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  influenza vaccine; intravenous immunoglobulin; vaccine safety

Mesh:

Substances:

Year:  2017        PMID: 29282756      PMCID: PMC6628912          DOI: 10.1111/pde.13370

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  15 in total

1.  Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system.

Authors:  R Ball; L K Ball; R P Wise; M M Braun; J A Beeler; M E Salive
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

2.  Erythema multiforme secondary to H1N1 vaccine.

Authors:  Irenawati Samad; Vui Heng Chong; Sabrina Su Hong Binti Abdul Azim Lim
Journal:  South Med J       Date:  2011-01       Impact factor: 0.954

Review 3.  Stevens-Johnson syndrome: pathogenesis, diagnosis, and management.

Authors:  Ribhi Hazin; Omar A Ibrahimi; Moustafa I Hazin; Arash Kimyai-Asadi
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

Review 4.  Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.

Authors:  Robert A Schwartz; Patrick H McDonough; Brian W Lee
Journal:  J Am Acad Dermatol       Date:  2013-08       Impact factor: 11.527

5.  Stevens-Johnson syndrome triggered by seasonal influenza vaccination and flucloxacillin: a pathogenetic hypothesis.

Authors:  John D Fleming; Abigail J Fogo; Daniel J Creamer
Journal:  Eur J Dermatol       Date:  2011 May-Jun       Impact factor: 3.328

6.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

7.  Persistent erythema multiforme: a report of three cases.

Authors:  M D Pavlović; D M Karadaglić; L O Kandolf; Z P Mijusković
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-01       Impact factor: 6.166

8.  Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.

Authors:  Philip S LaRussa; Kathryn M Edwards; Cornelia L Dekker; Nicola P Klein; Neal A Halsey; Colin Marchant; Roger Baxter; Renata J M Engler; Jennifer Kissner; Barbara A Slade
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

Review 9.  Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.

Authors:  Denise W Metry; Peter Jung; Moise L Levy
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

Review 10.  Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.

Authors:  Robert A Schwartz; Patrick H McDonough; Brian W Lee
Journal:  J Am Acad Dermatol       Date:  2013-08       Impact factor: 11.527

View more
  3 in total

1.  Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017.

Authors:  John R Su; Penina Haber; Carmen S Ng; Paige L Marquez; Graça M Dores; Silvia Perez-Vilar; Maria V Cano
Journal:  Vaccine       Date:  2019-12-20       Impact factor: 3.641

2.  Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics.

Authors:  Hossein Esmaeilzadeh; Shirin Farjadian; Soheila Alyasin; Hamid Nemati; Hesamodin Nabavizadeh; Elmira Esmaeilzadeh
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

Review 3.  An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.

Authors:  Louise M Gresham; Barbara Marzario; Jan Dutz; Mark G Kirchhof
Journal:  J Am Acad Dermatol       Date:  2021-01-19       Impact factor: 11.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.